Want to see XXII full AI Analyst Report?
XXII Stock Chart & Stats
$4.27
-$0.13(-3.04%)
At close: 4:00 PM EDT
$4.27
-$0.13(-3.04%)
Day’s Range― - ―
52-Week Range$3.61 - $801.00
Previous Close$3.97
Volume14.18K
Average Volume (3M)2.49M
Market Cap
$1.48M
Enterprise Value-$6.91
Total Cash (Recent Filing)$9.54M
Total Debt (Recent Filing)$1.32M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-214.80
Shares Outstanding345,124
10 Day Avg. Volume328,967
30 Day Avg. Volume2,485,312
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.70
Price to Sales (P/S)6.03
P/FCF Ratio-4.95
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-18
Revenue Forecast (FY)$32.50M
Bulls Say, Bears Say
Bulls Say
Strengthened Balance SheetLeverage has fallen sharply and equity is positive, giving the company durable financial flexibility. Low debt reduces refinancing risk and supports multi‑quarter investments in distribution and marketing, enabling the firm to pursue its commercialization plan without immediate debt pressure.
Regulatory Differentiation (FDA)Being the only FDA‑authorized product in its category creates a structural competitive advantage. Regulatory validation helps with retailer acceptance, public health credibility, and partner negotiations, raising barriers to entry and supporting longer‑term shelf presence and adoption.
Retail Distribution TractionConcrete distribution wins and an explicit plan to scale retail presence create a durable revenue-growth vector. Expanding outlets and adding marketing/sales headcount can build repeat sales and operational leverage over quarters if execution converts trials into sustained shelf velocity.
Bears Say
Negative Gross ProfitPersisting negative gross margins undermine the path to sustainable profitability; even with greater distribution, structural margin issues mean revenue growth may not translate to operating profits without pricing, product mix or cost improvements to fix unit economics.
Ongoing Cash BurnMaterial negative operating and free cash flow require continued external capital and raise dilution risk. This constrains multi‑period investments, forces prioritization of initiatives, and creates a funding overhang that can limit the company’s ability to sustain marketing and distribution scale‑up.
Contract Manufacturing LossThe scheduled end of a manufacturing engagement reduces contracted volumes and pressures capacity utilization and near‑term revenue. Replacing that business or repurposing capacity will take time, potentially raising unit costs and complicating the company’s execution of its retail growth plan.
22nd Century News
XXII FAQ
What was 22nd Century’s price range in the past 12 months?
22nd Century lowest stock price was $3.61 and its highest was $801.00 in the past 12 months.
What is 22nd Century’s market cap?
22nd Century’s market cap is $1.48M.
When is 22nd Century’s upcoming earnings report date?
22nd Century’s upcoming earnings report date is Aug 13, 2026 which is tomorrow.
How were 22nd Century’s earnings last quarter?
22nd Century released its earnings results on May 07, 2026. The company reported -$101.4 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is 22nd Century overvalued?
According to Wall Street analysts 22nd Century’s price is currently Overvalued.
Does 22nd Century pay dividends?
22nd Century does not currently pay dividends.
What is 22nd Century’s EPS estimate?
22nd Century’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 22nd Century have?
22nd Century has 345,124 shares outstanding.
What happened to 22nd Century’s price movement after its last earnings report?
22nd Century reported an EPS of -$101.4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.344%.
Which hedge fund is a major shareholder of 22nd Century?
Currently, no hedge funds are holding shares in XXII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
22nd Century
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
XXII Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed cautious optimism: management reported clear early commercial progress with sequential revenue growth, gross loss improvement, strategic retail distribution wins, regulatory validation (FDA authorization) and a stable cash position. However, material challenges remain — operating losses and negative adjusted EBITDA widened, profitability is below targets, low-margin contracts persist, and retail adoption is uneven. Management plans focused investments in marketing and distribution with a target of ~5,000 outlets by year-end, but execution risk and competitive headwinds mean near-term results may continue to be pressured.View all XXII earnings summariesTechnical Analysis
Universal
―
Turning Point Brands
―
Greenlane Holdings
―
Kaival Brands Innovations Group
―
Ispire Technology, Inc.
―
Ownership Overview
73.39% Insiders
1.35% Mutual Funds
<0.01% Other Institutional Investors
25.26% Public Companies and
Individual Investors